Infliximab therapy for Crohn's disease in the presence of chronic hepatitis C infection

Eur J Gastroenterol Hepatol. 2001 Feb;13(2):191-2. doi: 10.1097/00042737-200102000-00016.


Treatment of Crohn's disease with infliximab is an important drug therapy for patients with refractory and fistulating disease. There are concerns over its use in a proportion of Crohn's patients with concurrent hepatitis C infection, since there are theoretical risks of accelerated hepatic decompensation due to the immunomodulatory impact of infliximab. We report a patient with both Crohn's disease and ongoing active hepatitis C infection who underwent infliximab therapy, with no worsening of his liver function or PCR status.

Publication types

  • Case Reports

MeSH terms

  • Adult
  • Antibodies, Monoclonal / therapeutic use*
  • Crohn Disease / complications*
  • Crohn Disease / drug therapy*
  • Gastrointestinal Agents / therapeutic use*
  • Hepatitis C, Chronic / complications*
  • Humans
  • Infliximab
  • Male


  • Antibodies, Monoclonal
  • Gastrointestinal Agents
  • Infliximab